SCHEMBL5225633

SCHEMBL5225633

CCOC(=O)CN(Cc1cccc(O)c1)S(=O)(=O)N1CCc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.45
KMT2A Q03164 7/20 0.45
ALDH1A1 P00352 3/20 0.43
PKM P14618 2/20 0.43
NOTUM Q6P988 1/20 0.43
MAPT P10636 4/20 0.40
TSHR P16473 2/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
USP2 O75604 1/20 0.39
LMNA P02545 2/20 0.39
GAA P10253 1/20 0.39
TP53 P04637 1/20 0.39
MAPK1 P28482 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5228007 0.89 MEN1 (0.47) MEN1KMT2AALDH1A1PKMNOTUM
SCHEMBL5229661 0.88 L3MBTL1 (0.44) MEN1KMT2AALDH1A1PKMNOTUM
SCHEMBL5226093 0.84 MEN1 (0.43) MEN1KMT2AALDH1A1NOTUMMAPT
SCHEMBL5226874 0.84 MAPT (0.45) MEN1KMT2AALDH1A1NOTUMMAPT
SCHEMBL5229675 0.83 POLB (0.42) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL5223394 0.79 L3MBTL1 (0.41) ALDH1A1MAPTTSHRPOLBSMN1; SMN2
SCHEMBL5432230 0.79 PPARG (0.51)
SCHEMBL5440897 0.78 PPARG (0.52)
SCHEMBL5226465 0.77 PPARA (0.44) KMT2AALDH1A1LMNA
SCHEMBL5227672 0.77 PPARA (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same CRYSTAL GENOMICS, INC. (KR) 2007-11-01 US disclosed
EP-1778654-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME Crystalgenomics, Inc. (KR) 2007-05-02 EP disclosed
WO-2006006832-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME CRYSTALGENOMICS, INC. (KR) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same SULT2A1, SPTLC2, SGMS2 MEN1 4183/4885KMT2A 879/4885ALDH1A1 1086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.